Bliss GVS Pharma Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Latest quarter profit grew 83.5% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.40x)
- Company generates healthy free cash flow
- Company has a consistent dividend-paying track record
CONS
- A large part of profit comes from other income (43.8% of PBT)
- Company has a low return on equity of 7.0% over last 3 years
- Company has a low return on capital employed of 9.8%
- Valuation is stretched - P/E of 67.4 is well above its own 5-year median (23.3)
- Operating margins have contracted to 15.4% from 23.6%
- Company has delivered a poor profit growth of 7.5% over past five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1881.10 | 37.31 | 451338.90 | 0.85 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9570.55 | 86.86 | 254068.03 | 0.31 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4962.75 | 86.55 | 188767.06 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1150.00 | 25.42 | 114712.94 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1383.95 | 33.17 | 111803.57 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1945.50 | 96.14 | 105117.74 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1686.00 | 26.13 | 97008.71 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2112.00 | 17.47 | 96574.55 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1151.50 | 29.83 | 96113.39 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2305.85 | 46.63 | 95242.00 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2477.35 | 38.89 | 69916.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BLISSGVS | 725.20 | 56.62 | 7711.09 | 0.21 | 51.37 | 15.80 | 285.58 | 37.65 | 17.40 | 26.75 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109 | 171 | 161 | 164 | 149 | 183 | 180 | 156 | 163 | 190 | 165 | 212 | 222 | |
| 98 | 129 | 133 | 139 | 122 | 159 | 154 | 142 | 131 | 172 | 138 | 167 | 179 | |
| Operating Profit | 11 | 42 | 29 | 25 | 27 | 24 | 26 | 14 | 33 | 18 | 27 | 44 | 42 |
| OPM % | 10.14% | 24.70% | 17.76% | 15.35% | 17.95% | 12.94% | 14.33% | 8.80% | 20.05% | 9.47% | 16.30% | 20.87% | 19.16% |
| 7 | 11 | 8 | -33 | 7 | 10 | 12 | 9 | 11 | 26 | 8 | 10 | 9 | |
| Interest | 1 | 1 | 2 | 2 | 1 | 3 | 1 | 1 | 5 | 3 | 1 | 2 | 0 |
| Depreciation | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 9 |
| Profit before Tax | 11 | 46 | 29 | -15 | 26 | 24 | 30 | 14 | 31 | 33 | 25 | 44 | 51 |
| Tax % | 31.26% | 26.44% | 27.35% | 24.75% | 25.74% | 28.67% | 29.29% | 20.26% | 31.12% | 25.88% | 26.41% | 26.57% | 24.59% |
| Net Profit | 8 | 34 | 21 | -11 | 19 | 17 | 21 | 11 | 21 | 25 | 19 | 32 | 39 |
| 0.72 | 3.25 | 1.99 | -1.11 | 1.85 | 1.63 | 2.00 | 1.08 | 2.00 | 2.35 | 1.76 | 3.06 | 3.65 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 348 | 298 | 427 | 442 | 466 | 636 | 598 | 605 | 667 | 730 | 788 | |
| 247 | 209 | 333 | 342 | 374 | 527 | 508 | 498 | 576 | 611 | 657 | |
| Operating Profit | 101 | 88 | 93 | 100 | 91 | 109 | 90 | 107 | 92 | 119 | 131 |
| OPM % | 28.89% | 29.70% | 21.82% | 22.66% | 19.65% | 17.16% | 15.07% | 17.70% | 13.73% | 16.34% | 16.68% |
| 9 | 11 | 36 | 37 | 19 | 35 | 51 | -8 | 36 | 56 | 52 | |
| Interest | 9 | 7 | 3 | 7 | 6 | 4 | 10 | 6 | 7 | 11 | 6 |
| Depreciation | 6 | 6 | 6 | 9 | 14 | 14 | 15 | 24 | 27 | 31 | 32 |
| Profit before Tax | 95 | 87 | 120 | 122 | 91 | 126 | 116 | 70 | 94 | 133 | 154 |
| Tax % | 37.69% | 34.34% | 37.98% | 24.14% | 25.98% | 26.69% | 26.12% | 27.92% | 26.76% | 27.42% | 25.74% |
| Net Profit | 59 | 57 | 74 | 92 | 68 | 93 | 85 | 51 | 69 | 97 | 114 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 6.40 | 8.81 | 8.10 | 4.84 | 6.55 | 9.16 | — |
| Dividend Payout % | 10.47% | 18.09% | 13.86% | 5.59% | 7.64% | 5.59% | 6.09% | 10.34% | 7.64% | 16.38% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 8%
- 5 Years:
- 9%
- 3 Years:
- 7%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 4%
- 5 Years:
- 7%
- 3 Years:
- 4%
STOCK PRICE CAGR
- 10 Years:
- 16%
- 5 Years:
- 44%
- 3 Years:
- 93%
- 1 Year:
- 350%
RETURN ON EQUITY
- 10 Years:
- 10%
- 5 Years:
- 8%
- 3 Years:
- 7%
- Last Year:
- 9%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
| 481 | 531 | 593 | 673 | 735 | 831 | 918 | 970 | 1,042 | 1,133 | |
| 74 | 94 | 72 | 74 | 91 | 68 | 80 | 55 | 36 | 17 | |
| Trade Payables | 64 | 35 | 31 | 56 | 67 | 84 | 76 | 54 | 60 | 96 |
| 37 | 23 | 30 | 42 | 42 | 86 | 56 | 56 | 63 | 72 | |
| Total Liabilities | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,146 | 1,211 | 1,329 |
| 75 | 72 | 78 | 179 | 174 | 224 | 325 | 330 | 368 | 420 | |
| Capital Work in Progress | 2 | 0 | 43 | 0 | 2 | 22 | 3 | 8 | 21 | 4 |
| 22 | 19 | 19 | 19 | 18 | 18 | 18 | 19 | 19 | 19 | |
| 28 | 40 | 55 | 61 | 84 | 90 | 74 | 89 | 82 | 111 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 400 | 429 | 457 | |
| Cash & Bank | 84 | 70 | 93 | 87 | 120 | 149 | 85 | 169 | 171 | 111 |
| 456 | 492 | 447 | 510 | 548 | 576 | 635 | 131 | 122 | 208 | |
| Total Assets | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,146 | 1,211 | 1,329 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 76 | 59 | 98 | 95 | 90 | 145 | 82 | 82 | 97 | 123 | |
| Cash from Investing | -29 | 16 | -68 | -60 | -62 | -92 | -13 | -66 | -78 | -51 |
| Cash from Financing | -15 | -22 | 9 | -6 | -12 | -13 | -26 | -21 | -27 | -75 |
| -6 | 17 | -11 | -3 | -6 | 9 | 5 | -4 | -7 | -4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-04 - Bliss GVS Pharma Limited has informed the Exchange regarding the ESOP Allotment Committee of the Company at its meeting held today i.e. September 04,2026 has approved the allotment of 55,250 equity shares of the face value Re 1/- to the eligible employees who have exercised their stock options under the Bliss GVS Pharma Limited- Employee Stock Option Plan (Bliss GVS ESOP - 2019)
2026-09-02 - SBI Capital Markets Ltd has submitted to the Exchange a copy of Post offer advertisement in accordance with Regulation 18(12) of the SEBI (SAST) Regulations, 2011, as amended, for the attention of the public shareholders of the company.
2026-08-25 - Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Extension of Special Window for Re-Lodgement of Transfer Requests of Physical Shares
2026-08-21 - Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the Advertisement of the Postal Ballot Notice.
2026-08-20 - Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot
2026-08-14 - Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the extract of the statement of un-audited standalone andconsolidated financial results for the quarter ended June 30, 2026.
2026-08-12 - Bliss GVS Pharma Limited has informed the Exchange about General Updates regarding grant of options under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019.
2026-08-12 - Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026 along with the Limited Review Report and the draft of the Postal Ballot Notice seeking the approval of members of the Company for the appointment of Mr. Santosh Parab (DIN: 01622988) as a Director of the Company in the capacity of Non-Executive Non-Independent Director of the Company.
2026-08-11 - Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 31250 securities pursuant to ESOP/ESPS at its meeting held on August 11, 2026
News
Recent coverage and analyst commentary for BLISSGVS
Loading news…
AI Stock Analyst
Bliss GVS Pharma Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account